Ameliorating effect of erythropoietin in a severe case of COVID-19: case report.
Pan Afr Med J
; 43: 129, 2022.
Article
in English
| MEDLINE | ID: covidwho-2164238
ABSTRACT
The COVID-19 pandemic is arguably one of the greatest public health crises since the 1918 influenza pandemic. Although several vaccines have been approved and rolled out, effective antiviral treatment options are very limited. Here, we present a case of severe COVID-19 that failed to respond to the standard interventions and continued to deteriorate. On day 22 of his illness, after informed consent, the patient was administered 4000IU of erythropoietin (EPO) subcutaneously, in the hope of improving his O2 saturation. Positive response was observed in the patient within 24 hours. This prompted us to continued EPO treatment for a total of 42 days until full recovery and discharge. Our findings warrant further studies to ascertain the use of EPO in severe cases COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Erythropoietin
/
COVID-19
Type of study:
Case report
/
Experimental Studies
/
Observational study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Pan Afr Med J
Year:
2022
Document Type:
Article
Affiliation country:
Pamj.2022.43.129.35014
Similar
MEDLINE
...
LILACS
LIS